These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 19770373)

  • 1. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
    Arndt CA; Stoner JA; Hawkins DS; Rodeberg DA; Hayes-Jordan AA; Paidas CN; Parham DM; Teot LA; Wharam MD; Breneman JC; Donaldson SS; Anderson JR; Meyer WH
    J Clin Oncol; 2009 Nov; 27(31):5182-8. PubMed ID: 19770373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Hawkins DS; Chi YY; Anderson JR; Tian J; Arndt CAS; Bomgaars L; Donaldson SS; Hayes-Jordan A; Mascarenhas L; McCarville MB; McCune JS; McCowage G; Million L; Morris CD; Parham DM; Rodeberg DA; Rudzinski ER; Shnorhavorian M; Spunt SL; Skapek SX; Teot LA; Wolden S; Yock TI; Meyer WH
    J Clin Oncol; 2018 Sep; 36(27):2770-2777. PubMed ID: 30091945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study.
    Walterhouse DO; Lyden ER; Breitfeld PP; Qualman SJ; Wharam MD; Meyer WH
    J Clin Oncol; 2004 Apr; 22(8):1398-403. PubMed ID: 15007087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.
    Wolden SL; Lyden ER; Arndt CA; Hawkins DS; Anderson JR; Rodeberg DA; Morris CD; Donaldson SS
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1071-6. PubMed ID: 26581144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group.
    Gupta AA; Xue W; Harrison DJ; Hawkins DS; Dasgupta R; Wolden S; Shulkin B; Qumseya A; Routh JC; MacDonald T; Feinberg S; Crompton B; Rudzinski ER; Arnold M; Venkatramani R
    Lancet Oncol; 2024 Jul; 25(7):912-921. PubMed ID: 38936378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
    Meza JL; Anderson J; Pappo AS; Meyer WH;
    J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
    Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis.
    Kojima Y; Hashimoto K; Ando M; Yonemori K; Yamamoto H; Kodaira M; Yunokawa M; Shimizu C; Tamura K; Hosono A; Makimoto A; Fujiwara Y
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):391-7. PubMed ID: 22806306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
    Casey DL; Chi YY; Donaldson SS; Hawkins DS; Tian J; Arndt CA; Rodeberg DA; Routh JC; Lautz TB; Gupta AA; Yock TI; Wolden SL
    Cancer; 2019 Sep; 125(18):3242-3248. PubMed ID: 31174239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan AA; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
    J Clin Oncol; 2014 Nov; 32(31):3547-52. PubMed ID: 25267746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide.
    Arndt C; Hawkins D; Anderson JR; Breitfeld P; Womer R; Meyer W
    J Clin Oncol; 2004 May; 22(10):1894-901. PubMed ID: 15143082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
    Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
    J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
    Raney RB; Anderson JR; Barr FG; Donaldson SS; Pappo AS; Qualman SJ; Wiener ES; Maurer HM; Crist WM
    J Pediatr Hematol Oncol; 2001 May; 23(4):215-20. PubMed ID: 11846299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
    Ruymann FB; Vietti T; Gehan E; Wiener E; Wharam M; Newton WA; Maurer H
    J Pediatr Hematol Oncol; 1995 Nov; 17(4):331-7. PubMed ID: 7583389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Raney RB; Walterhouse DO; Meza JL; Andrassy RJ; Breneman JC; Crist WM; Maurer HM; Meyer WH; Parham DM; Anderson JR
    J Clin Oncol; 2011 Apr; 29(10):1312-8. PubMed ID: 21357783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
    Arndt CA; Hawkins DS; Meyer WH; Sencer SF; Neglia JP; Anderson JR
    Pediatr Blood Cancer; 2008 Jan; 50(1):33-6. PubMed ID: 17091486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Weigel BJ; Lyden E; Anderson JR; Meyer WH; Parham DM; Rodeberg DA; Michalski JM; Hawkins DS; Arndt CA
    J Clin Oncol; 2016 Jan; 34(2):117-22. PubMed ID: 26503200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
    Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS
    Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Intergroup Rhabdomyosarcoma Study-I. A final report.
    Maurer HM; Beltangady M; Gehan EA; Crist W; Hammond D; Hays DM; Heyn R; Lawrence W; Newton W; Ortega J
    Cancer; 1988 Jan; 61(2):209-20. PubMed ID: 3275486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children's Oncology Group.
    Raney B; Anderson J; Breneman J; Donaldson SS; Huh W; Maurer H; Michalski J; Qualman S; Ullrich F; Wharam M; Meyer W;
    Pediatr Blood Cancer; 2008 Jul; 51(1):17-22. PubMed ID: 18266224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.